Proactive Investors - Run By Investors For Investors

CloudTag issues shares at a premium

Not many companies manage to issue new shares at a premium to the prevailing market price
CloudTag issues shares at a premium
Spreadex Limited holds 20.82% on behalf of itself and discretionary clients, it was revealed today

Health-focused wearable technology developer CloudTag Inc (LON:CTAG) has raised £228,000 through the issue of shares at a premium to last night's closing mid-market price.

The company has issued 7.6mln shares at 3p a pop, prompting the shares to rise 9.5% on Wednesday morning to 3.01p.

CloudTag's shares closed at 2,75p on Tuesday.

Following the issue of the shares, the total number of ordinary shares in issue is 253,778,729, and of these Spreadex Limited holds 20.82% on behalf of itself and discretionary clients, it was revealed today.

The share issue follows a fund-raising earlier this month in which CloudTag responded to strong demand for its shares by issuing an additional 2.6mln shares to Spreadex at 2.5p each, raising £65,000 in the process to add to the £215,000 raised at the end of February through the issue of shares at 1.84p each.

View full CTAG profile View Profile

CloudTag Inc Timeline

January 17 2017

Related Articles

DS3 nuclear radiation detection device
December 19 2017
It was another period of good progress and upscaling in commercial activities with revenue growth driven by higher product sales in Kromek's key markets
Arnie, the Terminator
October 14 2017
The march of the machines ... Telit has placed itself firmly at the forefront of the next digital revolution - the Internet of Things (IoT).
February 08 2018
The firm has established connections with more than 4,000 universities in 160 countries enabling it to capture all of the intellectual property available

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.